02:30:46 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande



2024-11-28 Kvartalsrapport 2024-Q3
2024-08-29 Kvartalsrapport 2024-Q2
2024-05-29 Kvartalsrapport 2024-Q1
2024-05-27 X-dag ordinarie utdelning SANION 0.00 SEK
2024-05-25 Årsstämma 2024
2024-02-29 Bokslutskommuniké 2023
2024-01-16 Extra Bolagsstämma 2024
2023-11-30 Kvartalsrapport 2023-Q3
2023-08-31 Kvartalsrapport 2023-Q2
2023-05-25 Årsstämma 2023
2023-05-25 Kvartalsrapport 2023-Q1
2023-05-24 X-dag ordinarie utdelning SANION 0.00 SEK
2023-02-23 Bokslutskommuniké 2022
2022-11-17 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-08-18 Extra Bolagsstämma 2022
2022-05-27 X-dag ordinarie utdelning SANION 0.00 SEK
2022-05-25 Årsstämma 2022
2022-05-25 Kvartalsrapport 2022-Q1
2022-02-24 Bokslutskommuniké 2021
2021-11-18 Kvartalsrapport 2021-Q3
2021-09-16 Extra Bolagsstämma 2021
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-27 X-dag ordinarie utdelning SANION 0.00 SEK
2021-05-26 Kvartalsrapport 2021-Q1
2021-05-26 Årsstämma 2021
2021-03-17 Bokslutskommuniké 2020
2020-11-30 Kvartalsrapport 2020-Q3
2020-10-23 Extra Bolagsstämma 2020
2020-08-27 Kvartalsrapport 2020-Q2
2020-05-28 X-dag ordinarie utdelning SANION 0.00 SEK
2020-05-06 Kvartalsrapport 2020-Q1
2020-05-06 Årsstämma 2020
2020-02-07 Extra Bolagsstämma 2019
2020-02-07 Bokslutskommuniké 2019
2019-11-13 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-05-31 X-dag ordinarie utdelning SANION 0.00 SEK
2019-05-29 Kvartalsrapport 2019-Q1
2019-05-29 Årsstämma 2019
2019-02-21 Bokslutskommuniké 2018
2018-11-14 Kvartalsrapport 2018-Q3
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-25 X-dag ordinarie utdelning SANION 0.00 SEK
2018-05-24 Kvartalsrapport 2018-Q1
2018-05-24 Årsstämma 2018
2018-02-21 Bokslutskommuniké 2017
2018-01-19 Extra Bolagsstämma 2018
2017-11-15 Kvartalsrapport 2017-Q3
2017-08-23 Kvartalsrapport 2017-Q2
2017-05-24 X-dag ordinarie utdelning SANION 0.00 SEK
2017-05-23 Årsstämma 2017
2017-05-11 Kvartalsrapport 2017-Q1
2017-02-21 Bokslutskommuniké 2016
2016-10-13 Extra Bolagsstämma 2016
2016-05-11 X-dag ordinarie utdelning SANION 0.00 SEK
2016-05-10 Årsstämma 2016
2016-05-10 Kvartalsrapport 2016-Q1
2016-02-19 Bokslutskommuniké 2015
2015-11-20 Kvartalsrapport 2015-Q3
2015-09-04 Extra Bolagsstämma 2015
2015-08-31 Kvartalsrapport 2015-Q2
2015-05-21 X-dag ordinarie utdelning SANION 0.00 SEK
2015-05-20 Kvartalsrapport 2015-Q1
2015-05-20 Årsstämma 2015
2015-02-20 Bokslutskommuniké 2014
2014-11-21 Kvartalsrapport 2014-Q3
2014-08-22 Kvartalsrapport 2014-Q2


ListaSmall Cap Stockholm
Saniona är verksamt inom bioteknik. Idag bedrivs forskning och utveckling av läkemedel för behandling av nervsjukdomar samt övriga autoimmuna sjukdomar. Läkemedelsportföljen är bred och innefattar läkemedel som för närvarande befinner sig i olika kliniska faser. En del av arbetet utförs även i samarbete med andra aktörer inom läkemedelsbranschen. Saniona har huvudkontor i Glostrup.
2023-10-27 08:00:00

Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces that positive preclinical data on Saniona’s lead ion-channel drug candidate and phase 2 ready asset, SAN711, will be presented at the annual meeting of the Society for Neuroscience (SfN) 11th-15th November 2023, Washington DC. The data shows strong suppression of absence seizures, which demonstrates that SAN711 represents a novel precision approach for treatment of non-convulsive generalized seizures.

Professor Vincenzo Crunelli, Cardiff University, U.K., has evaluated SAN711 in the highly predictive and translatable animal model for absence seizures, the GAERS rat model. SAN711 demonstrated robust dose-related suppression of Spike-Wave-Discharges (SWDs), which are the EEG manifestations of absence seizures supporting clinical efficacy in absence seizures. Saniona has replicated Professor Vincenzo Crunelli’s exciting findings in the GAERS rat model at the contract research laboratory, Synapcell (France), where SAN711 was administrated peroral and compared to valproate, which is used as first line therapy today.

“This data provides convincing evidence that SAN711 with its unique differentiated pharmacological profile can target the root cause of the disease pathophysiology without liability for attentional impairments and embryofetal risks. It is a truly precision approach, where SAN711 aborts the SWDs by modulating the GABA a3 containing receptors in brain circuits where the seizures are initiated and maintained resulting in a potential new treatment for various epilepsy patients with non-convulsive seizures including patients with childhood absence seizures, juvenile absence seizures and various type of pediatric epileptic syndromes. As SAN711 is not activating other GABAA receptors, it is anticipated to be much better tolerated as compared to other antiepileptic medications. This was clearly supported by the outcome of the phase 1 study reported last year,” said Karin Sandager Nielsen, CSO of Saniona.

SAN711 is a unique subtype selective activator of GABAA α3 receptors. A Phase 1 study in 2022 demonstrated that SAN711 is safe and well tolerated in humans[1]. A parallel Positron Emission Tomography (PET) biomarker study confirmed that it is possible to reach relevant receptor occupancies at well tolerated doses opening for continued clinical development of the asset.

“This new data supports the development of SAN711 as a precision medicine in patient populations suffering from generalized seizures. Over the last year, we have made significant progress in our two other programs, SAN2219 and Kv7, positioned for epilepsy. We now have three active programs within epilepsy and our deep understanding of ion channel function is a cornerstone for our novel approaches in this field,” said Thomas Feldthus, CEO of Saniona.

More about absence seizures
Absence epilepsy is very prevalent in younger children and adolescents, where it comprises up to 10% of all childhood epilepsies[2]. Even though the majority is well treated, >20% remains refractory[3] to treatment and 40% continue to have absence seizures into adulthood[4]. Additionally, 30% have inherent cognitive impairments[5], and as first line treatment is to adversely affect cognition[6], there is a significant medical significant need for improved treatment options devoid of the limitations associated with standard-of-care today.

[1] Topline data https://saniona.com/newsroom/single-press-release/?slug=saniona-reports-positive-top-line-results-from-the-san711-phase-1-clinical-trial-3148ba6f
[2] Albuja A and Khan G., Absence Seizure StatsPearls Oct. 2022
[3] Trinka E et al., J. Neurol. 2004
[4] Trinka E et al., Acta Neurol. Scand. 2005
[5] Masur D et al., Neurol. 2013
[6] Glauser T.A et al., NEJM 2010